Zhen Huang1,2, Kai-Yu Deng2, Yu-Meng Deng2, Yan-Nian Hui3, Yan-Ping Song1,2. 1. The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong Province, China. 2. Department of Ophthalmology, General Hospital of Central Theater Command, Wuhan 430070, Hubei Province, China. 3. Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.
Abstract
AIM: To evaluate the long-term anatomical and visual outcomes of drusenoid pigment epithelial detachment (D-PED) in intermediate age-related macular degeneration (AMD) eyes treated with 577 nm yellow subthreshold micropulse laser (SML). METHODS: In this retrospective study, 21 eyes of 16 patients with D-PED in intermediate AMD were consecutively included and assessed. All the eyes were treated with 577 nm SML in several sessions according to D-PED growth status. The logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) were assessed at the initial visit and after treatment. Spectral-domain optical coherence tomography (SD-OCT) was performed to evaluate the D-PED lifecycle by volumetric calculations. Regression analysis was used to determine the breakpoint, growth, and collapse rate of the D-PED lesions. The progression to advanced AMD was also documented. RESULTS: All the eyes were treated with SML for 2.9±1.0 sessions. The mean follow-up period was 25.3±12.6mo. The BCVA was stable from the baseline to final visit. All the eyes were categorized into two groups according to the anatomical changes of the D-PED lesion: the collapse group (n=6, 28.6%) and non-collapse group (n=15, 71.4%). The change in logMAR BCVA did not differ significantly between the collapse group 0.00 (-0.31, 0.85) and non-collapse group 0.00 (0.00, 0.00; P=1). Regression analysis showed that the growth rate was significantly higher in the collapse group (0.090±0.095 mm3/mo) than in the non-collapse group (0.025±0.035 mm3/mo; P<0.001). One eye (4.8%) developed macular neovascularization at 11mo after SML treatment in the non-collapse group. Three eyes (14.3%) developed geographic atrophy (GA) in the collapse group. CONCLUSION: Compared to the natural course of D-PED reported by previous studies, our results preliminarily show that SML can alleviate visual loss and possibility of progression to advanced AMD in eyes with D-PED in intermediate AMD. A controlled clinical trial needs to further verify the benefit of the intervention. International Journal of Ophthalmology Press.
AIM: To evaluate the long-term anatomical and visual outcomes of drusenoid pigment epithelial detachment (D-PED) in intermediate age-related macular degeneration (AMD) eyes treated with 577 nm yellow subthreshold micropulse laser (SML). METHODS: In this retrospective study, 21 eyes of 16 patients with D-PED in intermediate AMD were consecutively included and assessed. All the eyes were treated with 577 nm SML in several sessions according to D-PED growth status. The logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) were assessed at the initial visit and after treatment. Spectral-domain optical coherence tomography (SD-OCT) was performed to evaluate the D-PED lifecycle by volumetric calculations. Regression analysis was used to determine the breakpoint, growth, and collapse rate of the D-PED lesions. The progression to advanced AMD was also documented. RESULTS: All the eyes were treated with SML for 2.9±1.0 sessions. The mean follow-up period was 25.3±12.6mo. The BCVA was stable from the baseline to final visit. All the eyes were categorized into two groups according to the anatomical changes of the D-PED lesion: the collapse group (n=6, 28.6%) and non-collapse group (n=15, 71.4%). The change in logMAR BCVA did not differ significantly between the collapse group 0.00 (-0.31, 0.85) and non-collapse group 0.00 (0.00, 0.00; P=1). Regression analysis showed that the growth rate was significantly higher in the collapse group (0.090±0.095 mm3/mo) than in the non-collapse group (0.025±0.035 mm3/mo; P<0.001). One eye (4.8%) developed macular neovascularization at 11mo after SML treatment in the non-collapse group. Three eyes (14.3%) developed geographic atrophy (GA) in the collapse group. CONCLUSION: Compared to the natural course of D-PED reported by previous studies, our results preliminarily show that SML can alleviate visual loss and possibility of progression to advanced AMD in eyes with D-PED in intermediate AMD. A controlled clinical trial needs to further verify the benefit of the intervention. International Journal of Ophthalmology Press.
Authors: Matthew D Davis; Ronald E Gangnon; Li-Yin Lee; Larry D Hubbard; Barbara E K Klein; Ronald Klein; Frederick L Ferris; Susan B Bressler; Roy C Milton Journal: Arch Ophthalmol Date: 2005-11
Authors: Catherine Cukras; Elvira Agrón; Michael L Klein; Frederick L Ferris; Emily Y Chew; Gary Gensler; Wai T Wong Journal: Ophthalmology Date: 2010-01-15 Impact factor: 12.079
Authors: Feifei Mao; Xiaohui Yang; Ke Yang; Xusheng Cao; Kai Cao; Jie Hao; Ye Zhang; Ningli Wang Journal: Invest Ophthalmol Vis Sci Date: 2019-12-02 Impact factor: 4.799
Authors: Robyn H Guymer; Zhichao Wu; Lauren A B Hodgson; Emily Caruso; Kate H Brassington; Nicole Tindill; Khin Zaw Aung; Myra B McGuinness; Erica L Fletcher; Fred K Chen; Usha Chakravarthy; Jennifer J Arnold; Wilson J Heriot; Shane R Durkin; Jia Jia Lek; Colin A Harper; Sanjeewa S Wickremasinghe; Sukhpal S Sandhu; Elizabeth K Baglin; Pyrawy Sharangan; Sabine Braat; Chi D Luu Journal: Ophthalmology Date: 2018-09-20 Impact factor: 12.079
Authors: Jan Tode; Elisabeth Richert; Stefan Koinzer; Alexa Klettner; Claus von der Burchard; Ralf Brinkmann; Ralph Lucius; Johann Roider Journal: Transl Vis Sci Technol Date: 2019-11-13 Impact factor: 3.283